Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

MORPHOSYS : AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 07:35am CET

MorphoSys AG / AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its AbD Serotec unit entered a research and supply agreement with the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (DFCI) in Boston. Dana-Farber is engaged in research activities within a project funded by the Defense Advanced Research Projects Agency (DARPA) of the United States Department of Defense, to develop transient immunity against life-threatening viral infections. AbD Serotec will provide the laboratory of Wayne Marasco, MD, PhD with research tools using its proprietary Slonomics technology platform. AbD Serotec will receive financial compensation and has preferred access to commercialization rights for products generated during the collaboration.

"We are delighted to provide a world-class research organization with innovative research tools. This alliance can lead to both short- and long-term value for AbD Serotec and the entire MorphoSys group in the infectious disease area," commented Dieter Feger, Senior Vice President and Head of AbD Serotec.

 

 

About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/:
http://www.morphosys.com/

 

 

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT® and Slonomics® are registered trademarks of MorphoSys; arYlaTM is a trademark of MorphoSys.

 

 

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

 

 

 

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

 

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

 

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

 

investors@morphosys.com:
mailto:investors@morphosys.com

 

Press Release:
http://hugin.info/130295/R/1533054/466934.pdf

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

HUG#1533054
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MORPHOSYS AG
12/06 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in..
12/06 MORPHOSYS PRESENTS UPDATED CLINICAL :
12/06 MORPHOSYS : Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at A..
11/29 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/28 MORPHOSYS : Announces That Its Licensee Janssen Has Submitted a Marketing Author..
11/25 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/22 CORRECTION OF A RELEASE FROM 21.11.2 : 05 CET - MorphoSys AG: Publication pursua..
11/21 MORPHOSYS AG : Publication pursuant to §26 sect.1 WpHG (the German Securities Tr..
11/21 MORPHOSYS AG : Notification of managers`transactions according to article 19 MAR
11/21 MORPHOSYS AG : Notification of managers`transactions according to article 19 MAR
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/22 Morphosys Ag (MPSYY) Investor Presentation - Slideshow
11/08 MorphoSys' (MPSYF) CEO Simon Moroney on Q3 2016 Results - Earnings Call Trans..
11/07 MorphoSys AG reports 9M results
10/04 Allergan Shows It Has Stomach For More GI Dealmaking
09/21 MorphoSys (MPSYY) Presents at Bank of America Merrill Lynch 2016 Global Healt..
Advertisement
Financials (€)
Sales 2016 49,9 M
EBIT 2016 -64,5 M
Net income 2016 -52,9 M
Finance 2016 238 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 21,5x
EV / Sales 2017 21,4x
Capitalization 1 311 M
More Financials
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 62,9 €
Spread / Average Target 40%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG-22.00%1 384
QUINTILES IMS HOLDINGS..14.10%19 286
INCYTE CORPORATION-7.21%18 957
CELLTRION, INC.--.--%9 997
LONZA GROUP AG9.20%9 261
SEATTLE GENETICS, INC.44.54%9 183
More Results